Suggested remit: To appraise the clinical and cost effectiveness of tolebrutinib within its marketing authorisation for treating non-relapsing secondary progressive multiple sclerosis.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6351
Project Team
- Project lead
- Emily Richards
Email enquiries
If you have any queries please email [email protected]
Stakeholders
- Companies sponsors
- Sanofi (tolebrutinib)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Brain and Spine Foundation
- Brain Charity
- MS-UK
- Multiple Sclerosis National Therapy Centres
- Multiple Sclerosis Society
- Multiple Sclerosis Trust
- Neuro Therapy Network
- Neurological Alliance
- Shift.ms
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Professional groups
- Association of British Neurologists
- British Association of Neuroscience Nurses
- British Geriatrics Society
- British Neuropathological Society
- British Society for Blood and Marrow Transplantation
- British Society of Neuroradiologists
- British Society of Rehabilitation Medicine
- Chartered Society of Physiotherapy
- Institute of Neurology
- London MS-AHSCT Collaborative Group
- National Neurosciences Advisory Group
- Primary Care and Community Neurology Society
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Occupational Therapists
- Royal College of Pathologists
- Royal College of Physicians
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Therapists in MS
- Transform MS for All
- UK Clinical Pharmacy Association
- UK Multiple Sclerosis Specialist Nurse Association
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- Novartis (siponimod)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health, Social Services and Public Safety for Northern Ireland
- Healthcare Improvement Scotland
- Health Technology Wales
- Medicines and Healthcare products Regulatory Agency
- Multiple Sclerosis Society Wales
- National Association of Primary Care
- National Pharmacy Association
- Neurological Alliance of Scotland
- NHS Confederation
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Wales Neurological Alliance
- Welsh Government
- Relevant research groups
- Brain Research UK
- British Neurological Research Trust
- Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group
- Genomics England
- MRC Clinical Trials Unit
- National Institute for Health Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 06 August 2025 | Invitation to participate |
| 25 April 2025 - 27 May 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6351 |
| 25 April 2025 | In progress. Scoping commencing |
| 28 April 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual